Get the Stockscreener App
5.87
7.56%
-0.48
After Hours:
5.88
0.010
+0.17%
Armata Pharmaceuticals Inc stock is traded at $5.87, with a volume of 21,139.
It is down -7.56% in the last 24 hours and up +4.26% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$6.35
Open:
$6.38
24h Volume:
21,139
Relative Volume:
0.08
Market Cap:
$213.71M
Revenue:
-
Net Income/Loss:
$-41.36M
P/E Ratio:
-3.5793
EPS:
-1.64
Net Cash Flow:
$-42.09M
1W Performance:
-5.93%
1M Performance:
+4.26%
6M Performance:
+170.51%
1Y Performance:
+181.01%
1-Day Range:
$5.87
$6.5499
1-Week Range:
$5.87
$6.59
52-Week Range:
$0.8981
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
5.87 | 231.18M | 0 | -41.36M | -42.09M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Coverage Initiated by Analysts at Jones Trading - Defense World
Jones Trading Initiates Coverage on Armata Pharmaceuticals (ARMP - GuruFocus
Jones Trading Initiates Coverage on Armata Pharmaceuticals (NYSEAMERICAN:ARMP) - MarketBeat
Jones Trading initiates coverage on Armata Pharmaceuticals stock with Buy rating - Investing.com Canada
Published on: 2026-01-05 08:37:29 - moha.gov.vn
Gap Down: Will Armata Pharmaceuticals Inc stock maintain dividend yieldMarket Growth Report & Risk Controlled Stock Pick Alerts - moha.gov.vn
Day Trade: Is Armata Pharmaceuticals Inc stock among top earnings playsLayoff News & Fast Exit and Entry Strategy Plans - moha.gov.vn
Will Armata Pharmaceuticals Inc stock maintain dividend yieldMarket Risk Summary & Growth Focused Entry Reports - moha.gov.vn
Pharma News: Will Armata Pharmaceuticals Inc stock gain from lower inflation2025 Market WrapUp & Real-Time Buy Signal Alerts - moha.gov.vn
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 2.7% HigherStill a Buy? - MarketBeat
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 2.7% Higher – Still a Buy? - Defense World
Aug Closing: Will Armata Pharmaceuticals Inc TG1N stock benefit from sector leadershipJuly 2025 Fed Impact & Consistent Growth Equity Picks - moha.gov.vn
Is Armata Pharmaceuticals Inc. stock trading near support levelsJuly 2025 Price Swings & Fast Moving Market Watchlists - DonanımHaber
Can Armata Pharmaceuticals Inc. stock deliver surprise earnings beatDip Buying & Safe Capital Growth Tips - Улправда
Can Armata Pharmaceuticals Inc. (TG1N) stock sustain double digit ROEJuly 2025 Catalysts & Accurate Entry/Exit Alerts - Улправда
Why Armata Pharmaceuticals Inc. stock attracts global investorsWeekly Profit Recap & Long-Term Growth Portfolio Plans - Улправда
Armata Pharmaceuticals Earnings Notes - Trefis
Will Armata Pharmaceuticals Inc. stock pay special dividendsMarket Volume Summary & Low Risk High Win Rate Stock Picks - Улправда
Why Armata Pharmaceuticals Inc. stock attracts wealthy investors2025 Buyback Activity & Free Real-Time Market Sentiment Alerts - Улправда
Will Armata Pharmaceuticals Inc. stock outperform energy sector in 2025July 2025 Setups & Advanced Technical Signal Analysis - Улправда
How Armata Pharmaceuticals Inc. stock reacts to bond yields2025 Volume Leaders & High Yield Equity Trading Tips - bolumsonucanavari.com
Will Armata Pharmaceuticals Inc. stock maintain dividend yieldJuly 2025 Setups & Smart Investment Allocation Tips - DonanımHaber
Is Armata Pharmaceuticals Inc. stock dividend growth reliableShare Buyback & Stepwise Trade Signal Implementation - DonanımHaber
Merger Talk: Can Armata Pharmaceuticals Inc. stock attract ESG capital inflowsWeekly Trade Review & Long-Term Growth Stock Strategies - DonanımHaber
Published on: 2025-12-19 11:47:18 - DonanımHaber
Will Armata Pharmaceuticals Inc. stock continue dividend increasesQuarterly Performance Summary & Verified Technical Signals - DonanımHaber
Can Armata Pharmaceuticals Inc. stock sustain revenue growth2025 Top Gainers & Safe Entry Trade Signal Reports - Улправда
Why Armata Pharmaceuticals Inc. (TG1N) stock is upgraded to buyCEO Change & AI Driven Stock Price Forecasts - Улправда
New Strong Sell Stocks for May 8th - sharewise.com
Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year? - MSN
Free cash flow per share of Armata Pharmaceuticals, Inc. – LS:A2PKLC - TradingView
Why Armata Pharmaceuticals Inc. (TG1N) stock benefits from AI revolution2025 Big Picture & AI Forecasted Stock Moves - Newser
Is Armata Pharmaceuticals Inc. (TG1N) stock testing key supportJuly 2025 Pullbacks & Verified Momentum Stock Watchlist - Newser
Why Armata Pharmaceuticals Inc. (TG1N) stock attracts HNW investorsPortfolio Growth Summary & Weekly Top Gainers Trade List - Newser
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? - MSN
Will Armata Pharmaceuticals Inc. stock announce special dividendBull Run & Real-Time Chart Breakout Alerts - Newser
Why Armata Pharmaceuticals Inc. stock is a strong buy call2025 Trade Ideas & Consistent Growth Equity Picks - Newser
Will Armata Pharmaceuticals Inc. stock split attract more investorsJuly 2025 Patterns & Weekly Top Stock Performers List - Newser
What is the fair value estimate for Armata Pharmaceuticals Inc. stock in 2025CPI Data & Long-Term Growth Plans - Newser
Will Armata Pharmaceuticals Inc. (TG1N) stock extend growth storyEarnings Risk Summary & Long-Term Safe Return Strategies - Newser
How Armata Pharmaceuticals Inc. (TG1N) stock compares with market leadersJuly 2025 Outlook & AI Powered Trade Plan Recommendations - Newser
Is Armata Pharmaceuticals Inc. stock considered safe havenMarket Movement Recap & Accurate Entry and Exit Point Alerts - Newser
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Up 12.8%Still a Buy? - MarketBeat
Market Catalysts: Can Armata Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 Snapshot & Safe Entry Trade Reports - BỘ NỘI VỤ
Will Armata Pharmaceuticals Inc. (TG1N) stock see insider accumulationQuarterly Portfolio Report & Smart Swing Trading Techniques - Newser
How risky is Armata Pharmaceuticals Inc. stock compared to peers2025 Trade Ideas & Real-Time Volume Analysis Alerts - Newser
Will Armata Pharmaceuticals Inc. (TG1N) stock sustain dividend payoutsWeekly Trend Report & AI Based Trade Execution Alerts - Newser
Is Armata Pharmaceuticals Inc. (TG1N) stock among top earnings playsEarnings Risk Report & Fast Momentum Entry Tips - Newser
How Armata Pharmaceuticals Inc. (TG1N) stock performs during market turbulenceJuly 2025 Gainers & Safe Capital Growth Stock Tips - Newser
Why analysts recommend Armata Pharmaceuticals Inc. stockDividend Hike & Daily Entry Point Trade Alerts - Newser
Is Armata Pharmaceuticals Inc. stock a buy before earnings resultsAnalyst Downgrade & Weekly Watchlist for Hot Stocks - Newser
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):